These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 12060771)

  • 1. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.
    Zimonjic DB; Pollock JL; Westervelt P; Popescu NC; Ley TJ
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13306-11. PubMed ID: 11087871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
    Westervelt P; Lane AA; Pollock JL; Oldfather K; Holt MS; Zimonjic DB; Popescu NC; DiPersio JF; Ley TJ
    Blood; 2003 Sep; 102(5):1857-65. PubMed ID: 12750176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
    Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
    Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.
    Pollock JL; Westervelt P; Kurichety AK; Pelicci PG; Grisolano JL; Ley TJ
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15103-8. PubMed ID: 10611345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.
    Agrawal-Singh S; Koschmieder S; Gelsing S; Stocking C; Stehling M; Thiede C; Thoennissen NH; Köhler G; Valk PJ; Delwel R; Mills K; Bäumer N; Tickenbrock L; Hansen K; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2010 Jun; 115(22):4507-16. PubMed ID: 20215640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
    Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
    He LZ; Tribioli C; Rivi R; Peruzzi D; Pelicci PG; Soares V; Cattoretti G; Pandolfi PP
    Proc Natl Acad Sci U S A; 1997 May; 94(10):5302-7. PubMed ID: 9144232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
    Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
    Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
    Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
    Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha.
    Sukhai MA; Wu X; Xuan Y; Zhang T; Reis PP; Dubé K; Rego EM; Bhaumik M; Bailey DJ; Wells RA; Kamel-Reid S; Pandolfi PP
    Oncogene; 2004 Jan; 23(3):665-78. PubMed ID: 14737102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
    Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.